After obtaining his degree in Biochemistry and Applied Clinical Biochemistry from UMIST in 2001, Andrew completed a PhD in Molecular Parasitology from the University of Manchester, studying the folate biosynthetic pathway of the malaria parasite Plasmodium falciparum. In 2006 he joined the Sinden lab at Imperial College, London, to study the sexual stages of Plasmodium, with an emphasis on developing transmission-blocking interventions (TBIs) to target the parasite within the mosquito host, inhibiting or preventing the onward transmission of malaria. He is currently a Principal Investigator in the DoLS, and his main interests focus on the identification of novel anti-malarial transmission blocking vaccine targets, vaccine delivery, the development of assays to examine TBI efficacy, and assessing the practical impact of introducing TBIs on populations of mosquitoes and vertebrate in both the laboratory and the field.
et al., 2017, A novel model fitted to multiple life stages of malaria for assessing efficacy of transmission-blocking interventions, Malaria Journal, Vol:16, ISSN:1475-2875
et al., 2017, Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase, Science Translational Medicine, Vol:9, ISSN:1946-6234
et al., 2017, Targeting the Conserved Fusion Loop of HAP2 Inhibits the Transmission of Plasmodium berghei and falciparum, Cell Reports, Vol:21, ISSN:2211-1247, Pages:2868-2878
et al., 2017, Protective efficacy of an IL-12-expressing baculoviral malaria vaccine., Parasite Immunol, Vol:39
et al., 2017, VECTORED PFCSP VACCINES BASED ON BACULOVIRUS DUAL EXPRESSION SYSTEM AND ADHU5 INDUCE STRONG PROTECTIVE EFFICACY AGAINST TRANSGENIC PLASMODIUM BERGHEI, 65th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH), AMER SOC TROP MED & HYGIENE, Pages:125-125, ISSN:0002-9637